One five-centre South West England consortium tracks 666 UK patients across all three approved CDK4/6 inhibitors.

The UK's HR+/HER2- metastatic breast cancer KOL universe is not evenly distributed across the country. A real-world evidence consortium spanning five South West England centres, Bristol, Bath, Taunton, Cheltenham, and Exeter, tracked 666 patients across all three NICE-approved CDK4/6 inhibitors: 537 on palbociclib, 85 on abemaciclib, and 44 on ribociclib. That kind of coordinated, multi-centre data generation does not happen by accident. It signals a KOL network structured around shared trial participation and joint publication, not isolated individual practices. Our KOL Universe gate starts by mapping exactly this kind of institutional concentration before any single physician is scored.

That structure changes how AXLRx tiers influence. A KOL who co-authors a five-centre consortium's real-world evidence paper carries a different kind of scientific weight than one working in isolation, and our Tier Classification gate scores that distinction directly, alongside NICE technology appraisal stakeholder submissions and ABC/ESMO guideline-committee roles. No named individual enters the workbook without a verification tag. Every KOL identity is checked against live trial registries, publication records, and guideline documentation, then marked Verified, Industry benchmark, or Requires client validation. A commercial team engaging the wrong tier wastes MSL capacity on a physician with no real influence over prescribing peers.

Publication count alone doesn't tell you who actually influences prescribing peers.

Five questions this report answers:

Q1 - Which UK institutions generate the real-world evidence that shapes HR+/HER2- mBC prescribing?

Q2 - How does AXLRx tier scientific influence without relying on publication count alone?

Q3 - What verification standard does every named KOL clear before shipping in the workbook?

Q4 - How many of the 666 South West England patients are on palbociclib versus ribociclib?

Q5 - What guideline-committee roles, like ABC and ESMO, does AXLRx's tiering model weight?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#KOLMapping #BreastCancer #CDK46Inhibitor #NICE #UK #MSL

Live report page:  https://axlrx.ai/breast-cancer-hr-positive-her2-negative/uk/kol-mapping/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-                                     hello@axlrx.ai

Web-                                     https://axlrx.ai/